LABP insider transaction filings
Landos Biopharma, Inc. — 10 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-05-23. Screen LABP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for LABP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Landos Biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-05-23 | 4 | Callori Fred — Director | Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) | EDGAR |
| 2024-05-23 | 4 | Batycky Alka — Director | Disposition to issuer (D): 3,600 (derivative) | EDGAR |
| 2024-05-23 | 4 | Garabedian Christopher Nishan — Director | Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) | EDGAR |
| 2024-05-23 | 4 | Cataldi Fabio — Chief Medical Officer | Disposition to issuer (D): 48,813 (derivative) · Disposition to issuer (D): 18,449 (derivative) · Disposition to issuer (D): 39,999 (derivative) | EDGAR |
| 2024-05-23 | 4 | Oakes Gregory — Chief Executive Officer, Director | Disposition to issuer (D): 54,454 (derivative) · Disposition to issuer (D): 47,529 (derivative) · Disposition to issuer (D): 167,724 (derivative) | EDGAR |
| 2024-05-23 | 4 | Adsett Roger — Director | Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 3,600 (derivative) | EDGAR |
| 2024-05-23 | 4 | Girao Tiago — Director | Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) | EDGAR |
| 2024-05-23 | 4 | MAYLEBEN TIMOTHY M — Director | Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,800 (derivative) | EDGAR |
| 2024-03-04 | 4 | Cataldi Fabio — Chief Medical Officer | Grant/award (A): 21,138 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Oakes Gregory — Chief Executive Officer, Director | Grant/award (A): 54,454 (derivative) @ $0 | EDGAR |
Recent 8-K events — Landos Biopharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-05-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2024-05-23 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-21 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LABP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →